Factors Associated with Hepatic Steatosis in Black African Subjects with Chronic Viral Hepatitis B in Côte d’Ivoire
- 1 Medical Sciences Training and Research Unit of Abidjan, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
- 2 Hepatology and Gastroenterology Unit, Yopougon University Hospital, Abidjan, Côte d’Ivoire
- 3 Hepatology and Gastroenterology Unit, Yopougon University Hospital, Abidjan, Côte d’Ivoire
- 4 Hepatology and Gastroenterology Unit, Yopougon University Hospital, Abidjan, Côte d’Ivoire
- 5 Hepatology and Gastroenterology Unit, Yopougon University Hospital, Abidjan, Côte d’Ivoire
- 6 Hepatology and Gastroenterology Unit, Yopougon University Hospital, Abidjan, Côte d’Ivoire
- 7 Hepatology and Gastroenterology Unit, Yopougon University Hospital, Abidjan, Côte d’Ivoire
- 8 Hepatology and Gastroenterology Unit, Yopougon University Hospital, Abidjan, Côte d’Ivoire
Abstract
Context/Objectives: With the progression of the global epidemic of obesity and metabolic syndrome, the coexistence of hepatic steatosis in patients with chronic viral hepatitis B (VHB) is becoming significant. The aim of this work was to determine the factors associated with hepatic steatosis assessed by a Fibroscan with Controlled Attenuation Parameter (CAP) in patients with chronic viral hepatitis B in C ô te d’Ivoire. Methods: This was a cross-sectional and analytical study. Data was collected from February 15 to July 31, 2020 in a private hospital structure in the city of Abidjan in C ô te d’Ivoire. We included 83 patients with chronic viral hepatitis B. These were black patients, having performed a Fibroscan/CAP during the recruitment period and consenting to participate in the study. Patients with significant alcohol consumption, a secondary cause of hepatic steatosis, or other liver disease regardless of the etiology associated with hepatitis B were not included. Results: The frequency of hepatic steatosis in chronic VHB carriers assessed by the CAP in our study population was 48.19% including 24.10% severe steatosis. Obesity and high LDL cholesterol were statistically correlated with the presence of steatosis in our patients. Patients who had steatosis on ultrasound were 5 times more likely to have steatosis on CAP. Significant fibrosis was not significantly associated with steatosis. Conclusion: Obesity and LDL hypercholesterolemia are the main factors associated with hepatic steatosis detected by Fibroscan/CAP in patients with chronic viral hepatitis B.
- Bernsmeier, C. and Heim, M. (2011) Stéatose hépatique non alcoolique et stéatohépatite non alcoolique. Forum Médical Suisse, 11, 53-57. https://doi.org/10.4414/fms.2011.07418
- Corrado, R.L., Torres, D.M. and Harrison, S.A. (2014) Review of Treatment Options for Nonalcoholic Fatty Liver Disease. Medical Clinics of North America, 98, 55-72. https://doi.org/10.1016/j.mcna.2013.09.001
- Organisation mondiale de gastro entérologie (2008) Recommandation pratique hépatite B. https://www.worldgastroenterology.org/UserFiles/file/guidelines/hepatitis-b-french-2008.pdf
- Minakari, M., Molaei, M., Shalmani, H.M., et al. (2009) Liver Steatosis in Patients with Chronic Hepatitis B Infection: Host and Viral Risk Factors. European Journal of Gastroenterology & Hepatology, 21, 512-516. https://doi.org/10.1097/MEG.0b013e328326792e
- Lin, C., Huang, X., Liu, H., et al. (2015) Interactions of Hepatitis B Virus Infection with Nonalcoholic Fatty Liver Disease: Possible Mechanisms and Clinical Impact. Digestive Diseases and Sciences, 60, 3513-3524. https://doi.org/10.1007/s10620-015-3772-z
- Boa, A., Douba, A., N’guessan, T.B., et al. (2017) Plaidoyer pour l’introduction du vaccin contre l’hépatite virale B à la naissance en C ôte d’Ivoire. Sante Publique, 29, 751-760. https://doi.org/10.3917/spub.175.0751
- Chalasani, N., Younossi, Z., Lavine, J.E., et al. (2018) The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 67, 328-357. https://doi.org/10.1002/hep.29367
- Haute autorité de santé (2014) Rapport d’évaluation technologique: Evaluation des méthodes non invasives de mesure de la fibrose hépatique dans l’hépatite B chronique Bilan initial et suivi des patients adultes non traités. https://www.has-sante.fr/upload/docs/application/pdf/2014-06/rapport_fibrose_mel.pdf
- Brener, S. (2015) Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. Ontario Health Technology Assessment Series, 15, 1-45.
- Ben Slama, T., Ksiaa, M., Souguir, A., et al. (2013) La stéatose hépatique au cours de l’hépatite chronique B: prévalence, facteurs de risque, et effet sur la fibrose et la réponse thérapeutique. La Tunisie Médicale, 91, 431-434.
- Seto, W.K., Hui, R.W.H., Mak, L.Y., et al. (2018) Association between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 16, 575-583.e2. https://doi.org/10.1016/j.cgh.2017.09.044